Document is current
Any future updates will be listed below
-
Authors
Zarbock, Alexander https://orcid.org/0000-0002-2124-1714
Forni, Lui
Koyner, Jay L.
Gómez, Hernando
Pannu, Neesh
Ostermann, Marlies
Bellomo, Rinaldo
Kellum, John A.
von Groote, Thilo
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (ZA 428/30-1)
Deutsche Forschungsgemeinschaft (ZA 428/29-1)
Deutsche Forschungsgemeinschaft (ZA 428/21-1)
Universitätsklinikum Münster
- License Information
-
More Information
Article History
Received: 9 May 2025
Accepted: 23 June 2025
First Online: 15 July 2025
Declarations
:
: AZ has received lecture and consultancy fees from Baxter, Fresenius, BioMerieux, Viatris, Guard Therapeutics, Novartis, Paion, AM Pharma, Alexion, Renibus, and Bayer as well as an unrestricted research grants from Baxter and BioMerieux. JLK received consulting fees from Alexion, Astute-Biomerieux, Baxter, Bioporto, Seastar, Novartis, Guard Therapeutics and research Funding from NIH, Astute Medical-Biomerieux, Bioporto, Fresenius Medical. JAK is a full-time employee of Spectral Medical and holds stock in the company. He also discloses consulting fees paid by AstraZeneca, Bayer, bioMérieux, Chugai Pharma, Mitsubishi Tenabe, and Novartis. MO has received research funding from Baxter and Biomerieux (paid to institution). LF, HG, NP, RB, and TvG have no conflict of interests.
